Literature DB >> 28164773

Apolipoprotein E-mediated Modulation of ADAM10 in Alzheimer's Disease.

Ben Shackleton1, Fiona Crawford2, Corbin Bachmeier3.   

Abstract

BACKGROUND: The APOE4 allele is the strongest genetic risk factor for Alzheimer's disease (AD). It has been associated with an accumulation of amyloid-β (Aβ) in the brain, which is produced through the sequential cleavage of the amyloid-β precursor protein (AβPP) by β - and γ-secretases. Alternatively, AβPP is also cleaved by α -secretases such as A Disintegrin and Metalloproteinase Domain-containing Protein 10 (ADAM10).
OBJECTIVE: While several studies have investigated the impact of apoE on β- and γ-secretase, interactions between apoE and α-secretases have not been fully examined. We investigated the effect of each apoE isoform on ADAM10 in vitro and in human cortex samples.
METHOD: ADAM10 activity and kinetics was assessed in cell-free assays and the biological activity of ADAM10 further investigated in 7WCHO cells over-expressing wild type AβPP through ELISA. Finally, ADAM10 expression and activity was observed in the soluble fraction of both control and Alzheimer's Disease human cortex samples through ELISA.
RESULTS: In a cell free assay, ADAM10 activity was found to be significantly lower in apoE4 samples compared to apoE2. 7WCHO cells over expressing wild type AβPP exposed to apoE4 demonstrated reduced formation of sAβPPα compared to other apoE isoforms. We also identified APOE and AD dependent changes in ADAM10 activity and expression in the soluble brain fraction of human brain cortex.
CONCLUSION: Overall, our data demonstrates an apoE isoform-dependent effect on ADAM10 function and AβPP processing which may describe the elevated amyloid levels in the brains of AD subjects carrying the APOE4 allele. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  ADAM10; APOE; Alzheimer's Disease; amyloid; apolipoprotein E; α-secretase

Mesh:

Substances:

Year:  2017        PMID: 28164773      PMCID: PMC6091859          DOI: 10.2174/1567205014666170203093219

Source DB:  PubMed          Journal:  Curr Alzheimer Res        ISSN: 1567-2050            Impact factor:   3.498


  41 in total

1.  Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease.

Authors:  C A McLean; R A Cherny; F W Fraser; S J Fuller; M J Smith; K Beyreuther; A I Bush; C L Masters
Journal:  Ann Neurol       Date:  1999-12       Impact factor: 10.422

2.  ADAM10, the rate-limiting protease of regulated intramembrane proteolysis of Notch and other proteins, is processed by ADAMS-9, ADAMS-15, and the gamma-secretase.

Authors:  Thomas Tousseyn; Amantha Thathiah; Ellen Jorissen; Tim Raemaekers; Uwe Konietzko; Karina Reiss; Elke Maes; An Snellinx; Lutgarde Serneels; Omar Nyabi; Wim Annaert; Paul Saftig; Dieter Hartmann; Bart De Strooper
Journal:  J Biol Chem       Date:  2009-02-11       Impact factor: 5.157

Review 3.  Alzheimer's disease.

Authors:  Henry W Querfurth; Frank M LaFerla
Journal:  N Engl J Med       Date:  2010-01-28       Impact factor: 91.245

4.  Apolipoprotein E alters the processing of the beta-amyloid precursor protein in APP(V717F) transgenic mice.

Authors:  Jean-Cosme Dodart; Kelly R Bales; Edward M Johnstone; Sheila P Little; Steven M Paul
Journal:  Brain Res       Date:  2002-11-15       Impact factor: 3.252

Review 5.  Amyloidosis and Alzheimer's disease.

Authors:  Jorge Ghiso; Blas Frangione
Journal:  Adv Drug Deliv Rev       Date:  2002-12-07       Impact factor: 15.470

6.  A disintegrin and metalloproteinase (ADAM)-mediated ectodomain shedding of ADAM10.

Authors:  Edward Parkin; Benjamin Harris
Journal:  J Neurochem       Date:  2009-01-22       Impact factor: 5.372

7.  A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model.

Authors:  Rolf Postina; Anja Schroeder; Ilse Dewachter; Juergen Bohl; Ulrich Schmitt; Elzbieta Kojro; Claudia Prinzen; Kristina Endres; Christoph Hiemke; Manfred Blessing; Pascaline Flamez; Antoine Dequenne; Emile Godaux; Fred van Leuven; Falk Fahrenholz
Journal:  J Clin Invest       Date:  2004-05       Impact factor: 14.808

Review 8.  APOE genotype effects on Alzheimer's disease onset and epidemiology.

Authors:  J Wesson Ashford
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

Review 9.  Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory.

Authors:  Paul R Turner; Kate O'Connor; Warren P Tate; Wickliffe C Abraham
Journal:  Prog Neurobiol       Date:  2003-05       Impact factor: 11.685

10.  A multifaceted role for apoE in the clearance of beta-amyloid across the blood-brain barrier.

Authors:  Corbin Bachmeier; Daniel Paris; David Beaulieu-Abdelahad; Benoit Mouzon; Michael Mullan; Fiona Crawford
Journal:  Neurodegener Dis       Date:  2012-05-08       Impact factor: 2.977

View more
  6 in total

1.  Frontal cortex and striatal cellular and molecular pathobiology in individuals with Down syndrome with and without dementia.

Authors:  Sylvia E Perez; Jennifer C Miguel; Bin He; Michael Malek-Ahmadi; Eric E Abrahamson; Milos D Ikonomovic; Ira Lott; Eric Doran; Melissa J Alldred; Stephen D Ginsberg; Elliott J Mufson
Journal:  Acta Neuropathol       Date:  2019-02-07       Impact factor: 17.088

2.  MicroRNA-455-3p as a Potential Biomarker for Alzheimer's Disease: An Update.

Authors:  Subodh Kumar; P Hemachandra Reddy
Journal:  Front Aging Neurosci       Date:  2018-02-23       Impact factor: 5.750

3.  Serum Thioredoxin-80 is associated with age, ApoE4, and neuropathological biomarkers in Alzheimer's disease: a potential early sign of AD.

Authors:  Anna Sandebring-Matton; Silvia Maioli; Julen Goikolea; Gorka Gerenu; Makrina Daniilidou; Francesca Mangialasche; Patrizia Mecocci; Tiia Ngandu; Juha Rinne; Alina Solomon; Miia Kivipelto; Angel Cedazo-Minguez
Journal:  Alzheimers Res Ther       Date:  2022-02-24       Impact factor: 6.982

4.  Effects of Molecular Hydrogen Assessed by an Animal Model and a Randomized Clinical Study on Mild Cognitive Impairment.

Authors:  Kiyomi Nishimaki; Takashi Asada; Ikuroh Ohsawa; Etsuko Nakajima; Chiaki Ikejima; Takashi Yokota; Naomi Kamimura; Shigeo Ohta
Journal:  Curr Alzheimer Res       Date:  2018-03-14       Impact factor: 3.498

Review 5.  Alpha-Secretase ADAM10 Regulation: Insights into Alzheimer's Disease Treatment.

Authors:  Rafaela Peron; Izabela Pereira Vatanabe; Patricia Regina Manzine; Antoni Camins; Márcia Regina Cominetti
Journal:  Pharmaceuticals (Basel)       Date:  2018-01-29

6.  Reduced TREM2 activation in microglia of patients with Alzheimer's disease.

Authors:  Yuumi Okuzono; Hiroyuki Sakuma; Shuuichi Miyakawa; Masataka Ifuku; Jonghun Lee; Debashree Das; Antara Banerjee; Yang Zhao; Koji Yamamoto; Tatsuya Ando; Shuji Sato
Journal:  FEBS Open Bio       Date:  2021-09-28       Impact factor: 2.693

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.